Ligand Pharmaceuticals Inc., of San Diego, reported top-line results from a phase II trial testing LGD-6972, an oral, small-molecule glucagon receptor antagonist, as an adjunct to diet and exercise in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.